Equifax Inc. EFX is currently benefiting from its technology transformation and strong customer base.
EFX’s revenues for 2022 and 2023 are expected to improve 3.6% from the respective year-ago reported figures.
Factors That Augur Well
Equifax’s ongoing cloud data and technology transformation aims to drive innovation and product development, and strengthen customer and partner integration. As part of the shift, EFX is migrating to a public cloud environment involved in virtual private cloud deployment techniques. EFX is focused on streamlining customers’ access to its analytical platforms.
Moreover, EFX concentrates on expanding and strengthening its customer base with efforts to deliver multi-data solutions by expanding differentiated data assets and analytics through organic growth, mergers and acquisitions, and partnerships. Equifax uses proprietary advanced analytical platforms, machine learning, artificial intelligence and advanced visualization tools.
Equifax’s current ratio at the end of the September quarter was pegged at 0.64, lower than 1.53 reported at the end of the prior-year quarter. A decreasing current ratio is not desirable as it highlights a company’s difficulty in fulfilling its short-term debt obligations.
Zacks Rank and Stocks to Consider
Equifax currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Booz Allen carries a Zacks Rank #2 (Buy) at present. BAH has a long-term earnings growth expectation of 8.9%.
Booz Allen delivered a trailing four-quarter earnings surprise of 8.8%, on average.
Paychex carries a Zacks Rank of 2 at present. PAYX has a long-term earnings growth expectation of 7.5%.
Paychex delivered a trailing four-quarter earnings surprise of 8.6%, on average.
Cross Country Healthcare is currently Zacks #2Ranked. CCRN has a long-term earnings growth expectation of 6%.
CCRN delivered a trailing four-quarter earnings surprise of 10.1%, on average.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Paychex, Inc. (PAYX): Free Stock Analysis Report
Equifax, Inc. (EFX): Free Stock Analysis Report
Booz Allen Hamilton Holding Corporation (BAH): Free Stock Analysis Report
Cross Country Healthcare, Inc. (CCRN): Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.